Drug Search Results
More Filters [+]

Sembragiline

Alternative Names: sembragiline, ro-4602522, ro 4602522, ro4602522
Latest Update: 2021-07-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: MAO-b Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sembragiline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Alzheimer Disease

Phase 1: Healthy Volunteers|Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

3 Armed RCT

N/A

Not yet recruiting

Obesity

2023-09-30

MAyflOwer RoAD

P2

Completed

Alzheimer Disease

2015-06-12

2012-000943-29

P2

Completed

Alzheimer Disease

2015-06-03

JapicCTI-142605

P1

Completed

Alzheimer Disease

2015-05-01

Recent News Events